Deutsche Bank Ag\ Vor Biopharma Inc. Transaction History

Deutsche Bank Ag\

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.66 - $2.63 $52,846 - $83,726	31,835 New	31,835 $71,000
Q2 2022 Aug 11, 2022	SELL	$3.89 - $6.44 $41,300 - $68,373	-10,617 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$6.04 - $12.23 $7,356 - $14,896	-1,218 Reduced 10.29%	10,617 $64,000
Q4 2021 Feb 11, 2022	BUY	$11.32 - $18.02 $6,814 - $10,848	602 Added 5.36%	11,835 $138,000
Q3 2021 Nov 04, 2021	BUY	$12.24 - $20.38 $48,396 - $80,582	3,954 Added 54.32%	11,233 $176,000
Q2 2021 Aug 11, 2021	SELL	$18.65 - $38.78 $4,214 - $8,764	-226 Reduced 3.01%	7,279 $136,000
Q1 2021 May 13, 2021	BUY	$30.96 - $54.08 $232,354 - $405,870	7,505 New	7,505 $323,000

41.2M

9.3K

100

Ticker VOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,056,300
Market Cap $32.7M
Description
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AM...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.